Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia
Leukemia & Myelodysplastic Syndromes (MDS)
-
-
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
-
Assessment of Financial Difficulty in Participants with Chronic Lymphocytic Leukemia and Multiple Myeloma
-
Topotecan in Treating Patients With Myelodysplastic Syndrome
-
Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)
-
Combination Chemotherapy in Treating Patients With Non-Hodgkin’s Lymphoma or Acute Lymphocytic Leukemia
-
Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia
-
Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
-
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
-
Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Categories
Alliance Committee
Browse by Year